You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康寧傑瑞製藥-B(09966.HK):訂立兩份技術開發協議
格隆匯 03-31 21:36

格隆匯3月31日丨康寧傑瑞製藥-B(09966.HK)宣佈,公司全資附屬公司江蘇康寧傑瑞及蘇州康寧傑瑞於2020年3月31日就公司三款候選藥物,即KN019、KN026及KN035的工藝優化和轉移訂立一份技術開發協議及就公司的一款候選藥物KN052的工藝放大研究訂立一份技術開發協議。

根據行業慣例,公司委聘合約研究機構等相關服務供應商於臨牀前期研究及臨牀試驗中提供若干服務。於公司招股章程中披露的重組前,江蘇康寧傑瑞為蘇州康寧傑瑞的附屬公司,因此其對公司的需求及要求十分熟悉。蘇州康寧傑瑞對於技術開發協議所涉及的工藝優化服務擁有豐富的經驗和業界領先的能力。考慮到蘇州康寧傑瑞提供相關技術開發服務的品質,其就該等交易的報價與其他獨立第三方供應商相比更具競爭力。公司相信此次合作有助於優化相關產品現有的生產工藝,降低生產成本。公司相信該等協議的履行會對公司相關產品之研發、製造及商業化帶來積極影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account